Xolair is a medicine containing the active ingredient(s) omalizumab. On this page you will find out more about Xolair, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: omalizumab
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Xolair (1 x 150 mg vial, 1 x 1.2 mL inert diluent ampoule), 1 pack
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Allergic Asthma: Children 6 to < 12 years of age - In children aged 6 to <12 years, Xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin E levels corresponding to the recommended dose range (see Table 10 under Dosage and Administration). Adults and adolescents >= 12 years of age - Xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin E levels corresponding to the recommended dose range (see Table 10 under Dosage and Administration). Chronic Spontaneous Urticaria (CSU): Xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.
Table of characteristics
1 active vial & 1 diluent ampoule: Prescription Only Medicine, or Prescription Animal Remedy
|Visual appearance||White to off white cake.|
|Dosage Form||Injection, powder for|
|Route of administration||Subcutaneous|
|Visual appearance||Clear, colourless solution.|
|Dosage Form||Injection, solution|
|Route of administration||Subcutaneous|
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Reconstituted Solution see label for shelf life|
|Life time||4 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Xolair vial (Powder for injection) - myDr.com.au
Xolair vial (Powder for injection) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Your asthma medicine
Preventers, relievers and severe asthma treatments
Read more on Asthma Australia website
Found 1 results
Use of anti-IgE treatment for allergic bronchopulmonary aspergillosis in people with cystic fibrosis | Cochrane
We reviewed the evidence about the effect of anti-IgE therapy for treating allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Read more on Cochrane (Australasian Centre) website